TY - JOUR AU - Nagaratna Shivanandappa AU - Dr. Shalini N Swamy AU - Dr. Sandeep Kumar S AU - Dr. Suma Sheshadri AU - Dr. Venkateshaiah Reddihalli Pallavi AU - Dr. Ramesh Gawari PY - 2021/06/30 Y2 - 2024/03/28 TI - Aberrant promoter hypermethylation of RAR-β in endometrial carcinoma- an Indian study. JF - International Journal of Medical Research and Review JA - Int J Med Res Rev VL - 9 IS - 3 SE - Original Article DO - 10.17511/ijmrr.2021.i03.05 UR - https://ijmrr.medresearch.in/index.php/ijmrr/article/view/1294 AB - Endometrial cancer is the seventh most common cancer in women worldwide with and age standardized rate of 8.4 per 100,000 women. Epigenetic alterations such as promoter hypermethylation of TSGs are known to be early events in carcinogenesis. The aim of the present study, we assessed the aberrant promoter hypermethylation pattern of RAR-β in 78 endometrial cancer samples.Methods: DNA was isolated from endometrial carcinoma samples and normal tissues and aberrant promoter hypermethylation was assessed using nested and methylation specific PCR. Chi square test was used for statistical analysis and a p-value<0.05 was considered to be statistically significant.Results: 40 of the 78 (51.28%) endometrial carcinoma sample showed aberrant hypermethylation of RAR-β gene. Methylation status in each histological subtype, grade and stage of the disease was also assessed.Conclusion: Aberrant hypermethylation is an important early epigenetic alteration that occurs during tumorigenesis. The Data shown here reports that promoter hypermethylation of RAR-β occurs in endometrial carcinoma and therefore could be used as a potential marker for early diagnosis and prognosis of the disease. ER -